NCT00500110 - Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Prostate Cancer

Interventions

DRUG

Docetaxel

30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.

DRUG

Imatinib Mesylate

600 mg by mouth (PO) Daily x 42 Days.

DRUG

Leuprolide

Hormone injections given every other month or every 3 months, as determined by the doctor.

DRUG

Goserelin Acetate

Hormone injections given every other month or every 3 months, as determined by the doctor.

Trial Locations (1)

U.T.M.D. Anderson Cancer Center, Houston